[1] Bain BJ,Béné MC, Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia. Acta haematologica. 2019 Apr 9;     [PubMed PMID: 30965338]
[2] Naymagon L,Marcellino B,Mascarenhas J, Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. Blood reviews. 2019 Mar 30;     [PubMed PMID: 30948162]
[3] Medeiros BC,Chan SM,Daver NG,Jonas BA,Pollyea DA, Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. American journal of hematology. 2019 Apr 3;     [PubMed PMID: 30945331]
[4] Hartmann L,Metzeler KH, Clonal hematopoiesis and pre-leukemia -genetics, biology and clinical implications. Genes, chromosomes     [PubMed PMID: 30939217]
[5] Boddu PC,Zeidan AM, Myeloid disorders after autoimmune disease. Best practice     [PubMed PMID: 30927978]
[6] Liu XJ,Huang XJ,Xu LP,Liu KY,Zhang XH,Yan CH,Wang Y, [Effects of pre-transplant course on prognosis of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2019 Mar 14;     [PubMed PMID: 30929382]
[7] Leisch M,Jansko B,Zaborsky N,Greil R,Pleyer L, Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation? Cancers. 2019 Feb 21;     [PubMed PMID: 30795628]
[8] Dong XY,Li YL,Jiang L,Wu CY,Shang BJ,Zhang L,Cheng W,Zhu ZM, [Correlation between myeloperoxidase expression and gene alterations and prognosis in acute myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2019 Jan 14;     [PubMed PMID: 30704227]
[9] Schmid C,Labopin M,Schaap N,Veelken H,Schleuning M,Stadler M,Finke J,Hurst E,Baron F,Ringden O,Bug G,Blaise D,Tischer J,Bloor A,Esteve J,Giebel S,Savani B,Gorin NC,Ciceri F,Mohty M,Nagler A, Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. British journal of haematology. 2019 Mar;     [PubMed PMID: 30467839]
[10] Nabhan C,Kamat S,Karl Kish J, Acute myeloid leukemia in the elderly: what constitutes treatment value? Leukemia     [PubMed PMID: 30407103]
[11] Duan WB,Gong LZ,Jia JS,Zhu HH,Zhao XS,Jiang Q,Zhao T,Wang J,Qin YZ,Huang XJ,Jiang H, [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences. 2017 Dec 18;     [PubMed PMID: 29263470]
[12] Lin M,Chen B, Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). Drug design, development and therapy. 2018;     [PubMed PMID: 29750014]
[13] Schoen MW,Woelich SK,Braun JT,Reddy DV,Fesler MJ,Petruska PJ,Freter CE,Lionberger JM, Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk. Leukemia research. 2018 May;     [PubMed PMID: 29574395]
[14] Strickland SA,Shaver AC,Byrne M,Daber RD,Ferrell PB,Head DR,Mohan SR,Mosse CA,Moyo TK,Stricker TP,Vnencak-Jones C,Savona MR,Seegmiller AC, Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leukemia research. 2018 Feb;     [PubMed PMID: 29310020]
[15] Fujiwara Y,Yamaguchi H,Yui S,Tokura T,Inai K,Onai D,Omori I,Marumo A,Yamanaka S,Sakaguchi M,Terada K,Nakagome S,Arai K,Kitano T,Okabe M,Okamoto M,Tamai H,Nakayama K,Tajika K,Wakita S,Inokuchi K, Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia. International journal of laboratory hematology. 2019 Apr 10;     [PubMed PMID: 30970181]
[16] Niu P,Yao B,Wei L,Zhu H,Fang C,Zhao Y, Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia. Blood cells, molecules     [PubMed PMID: 30954792]